KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Accumulated Expenses: 2020-2025

Historic Accumulated Expenses for Royalty Pharma (RPRX) over the last 5 years, with Sep 2025 value amounting to $29.0 million.

  • Royalty Pharma's Accumulated Expenses fell 24.39% to $29.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.0 million, marking a year-over-year decrease of 24.39%. This contributed to the annual value of $98.1 million for FY2024, which is 89.74% up from last year.
  • As of Q3 2025, Royalty Pharma's Accumulated Expenses stood at $29.0 million, which was down 66.07% from $85.6 million recorded in Q2 2025.
  • Royalty Pharma's 5-year Accumulated Expenses high stood at $98.1 million for Q4 2024, and its period low was $10.3 million during Q1 2021.
  • Over the past 3 years, Royalty Pharma's median Accumulated Expenses value was $38.4 million (recorded in 2024), while the average stood at $42.8 million.
  • In the last 5 years, Royalty Pharma's Accumulated Expenses surged by 204.98% in 2024 and then declined by 24.39% in 2025.
  • Royalty Pharma's Accumulated Expenses (Quarterly) stood at $57.7 million in 2021, then decreased by 6.13% to $54.2 million in 2022, then fell by 4.58% to $51.7 million in 2023, then soared by 89.74% to $98.1 million in 2024, then fell by 24.39% to $29.0 million in 2025.
  • Its Accumulated Expenses was $29.0 million in Q3 2025, compared to $85.6 million in Q2 2025 and $19.2 million in Q1 2025.